(M3V) MeVis Medical Solutions - Ratings and Ratios
Exchange: XETRA •
Country: Germany •
Currency: EUR •
Type: Common Stock •
ISIN: DE000A0LBFE4
Medical, Imaging, Diagnostics, Software, Visualization, Analysis, Training
M3V EPS (Earnings per Share)
M3V Revenue
Description: M3V MeVis Medical Solutions
MeVis Medical Solutions AG develops, markets, and sells software for recording, analyzing, and evaluating image data to manufacturers of medical devices, providers of medical IT platforms, and clinical end customers in the United States and Europe. The company's clinical focuses are image-based early detection and diagnosis of epidemiologically important diseases, such as breast, lung, liver, and neurological diseases. It offers X-ray based radiography procedures, including computed tomography, mammography/digital tomosynthesis, magnetic resonance imaging, and digital sonography; and provides services in the field of software programming for medical technology companies, which comprise provision of software developers, product and project managers, application specialists, and test engineers. The company also offers three-dimensional technical visualizations; and interactive online training to enhance the diagnostic skills of clinicians, as well as internet-based special applications in teleradiology. In addition, it develops and sells software licenses; and provides services for technical visualization and online training. The company was incorporated in 1997 and is based in Bremen, Germany. MeVis Medical Solutions AG is a subsidiary of Varex Imaging Corporation., Web URL: https://www.mevis.de
Additional Sources for M3V Stock
M3V Stock Overview
Market Cap in USD | 52m |
Sector | Healthcare |
Industry | Health Information Services |
GiC Sub-Industry | Health Care Technology |
IPO / Inception |
M3V Stock Ratings
Growth Rating | -19.0 |
Fundamental | 25.1 |
Dividend Rating | 32.7 |
Rel. Strength | 7.93 |
Analysts | - |
Fair Price Momentum | 22.85 EUR |
Fair Price DCF | 1.11 EUR |
M3V Dividends
Dividend Yield 12m | 3.89% |
Yield on Cost 5y | 2.99% |
Annual Growth 5y | 0.00% |
Payout Consistency | 68.7% |
Payout Ratio | 40.3% |
M3V Growth Ratios
Growth Correlation 3m | -90.1% |
Growth Correlation 12m | 58.9% |
Growth Correlation 5y | -61.1% |
CAGR 5y | -3.54% |
CAGR/Max DD 5y | -0.09 |
Sharpe Ratio 12m | -0.32 |
Alpha | -4.84 |
Beta | 0.116 |
Volatility | 0.19% |
Current Volume | 0k |
Average Volume 20d | 0k |
Stop Loss | 22.6 (-8.1%) |
What is the price of M3V shares?
As of July 15, 2025, the stock is trading at EUR 24.60 with a total of 0 shares traded.
Over the past week, the price has changed by +0.82%, over one month by -1.60%, over three months by -4.65% and over the past year by +0.44%.
As of July 15, 2025, the stock is trading at EUR 24.60 with a total of 0 shares traded.
Over the past week, the price has changed by +0.82%, over one month by -1.60%, over three months by -4.65% and over the past year by +0.44%.
Is MeVis Medical Solutions a good stock to buy?
Neither. Based on ValueRay´s Fundamental Analyses, MeVis Medical Solutions is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.09 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of M3V is around 22.85 EUR . This means that M3V is currently overvalued and has a potential downside of -7.11%.
Neither. Based on ValueRay´s Fundamental Analyses, MeVis Medical Solutions is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 25.09 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of M3V is around 22.85 EUR . This means that M3V is currently overvalued and has a potential downside of -7.11%.
Is M3V a buy, sell or hold?
MeVis Medical Solutions has no consensus analysts rating.
MeVis Medical Solutions has no consensus analysts rating.
What are the forecasts for M3V share price target?
According to our own proprietary Forecast Model, M3V MeVis Medical Solutions will be worth about 24.7 in July 2026. The stock is currently trading at 24.60. This means that the stock has a potential upside of +0.53%.
According to our own proprietary Forecast Model, M3V MeVis Medical Solutions will be worth about 24.7 in July 2026. The stock is currently trading at 24.60. This means that the stock has a potential upside of +0.53%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 24.7 | 0.5% |